24-norursodeoxycholic acid has been researched along with ursodeoxycholic acid in 35 studies
| Studies (24-norursodeoxycholic acid) | Trials (24-norursodeoxycholic acid) | Recent Studies (post-2010) (24-norursodeoxycholic acid) | Studies (ursodeoxycholic acid) | Trials (ursodeoxycholic acid) | Recent Studies (post-2010) (ursodeoxycholic acid) |
|---|---|---|---|---|---|
| 35 | 2 | 27 | 4,592 | 626 | 1,561 |
| Protein | Taxonomy | 24-norursodeoxycholic acid (IC50) | ursodeoxycholic acid (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 3.6 | |
| M1-family alanyl aminopeptidase | Plasmodium falciparum 3D7 | 2.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 5 (14.29) | 29.6817 |
| 2010's | 26 (74.29) | 24.3611 |
| 2020's | 3 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Auwerx, J; Gioiello, A; Hofmann, AF; Macchiarulo, A; Pellicciari, R; Saladin, R; Sato, H; Schoonjans, K; Thomas, C; Une, M | 1 |
| Gilmer, JF; Keaveney, R; Kelleher, D; Long, A; Majer, F; Peta, VK; Sharma, R; Wang, J | 1 |
| Byrne, AM; Gilmer, JF; Kelleher, D; Long, A; Majer, F; Prichard, D; Sharma, R | 1 |
| Cipriani, S; D'Amore, C; Di Leva, FS; Festa, C; Fiorucci, S; Limongelli, V; Masullo, D; Monti, MC; Novellino, E; Renga, B; Sepe, V; Zampella, A | 1 |
| Hagey, LR; Hofmann, AF; Schteingart, CD; Setchell, KD | 1 |
| Cover, C; Denk, H; Fickert, P; Fuchsbichler, A; Hofmann, AF; Jaeschke, H; Liu, J; Marschall, HU; Trauner, M; Tsybrovskyy, O; Waalkes, MP; Wagner, M; Zatloukal, K; Zollner, G | 1 |
| O'Leary, JG; Pratt, DS | 1 |
| Alpini, G; Glaser, SS | 1 |
| Denk, H; Fickert, P; Fiorotto, R; Fuchsbichler, A; Gumhold, J; Halilbasic, E; Hofmann, AF; Langner, C; Maitra, U; Marschall, HU; Moustafa, T; Silbert, D; Spirli, C; Strazzabosco, M; Trauner, M; Zatloukal, K | 1 |
| Paumgartner, G | 1 |
| Beraza, N; Bischoff, SC; Boekschoten, M; Ehedego, H; Mueller, M; Ofner-Ziegenfuss, L; Trauner, M; Trautwein, C | 1 |
| Fabris, L; Fiorotto, R; Hoque, R; Scirpo, R; Spirli, C; Strazzabosco, M; Trauner, M | 1 |
| Fauler, G; Fickert, P; Frank, S; Guelly, C; Gumhold, J; Höfler, G; Kratky, D; Lass, A; Magnes, C; Moustafa, T; Reicher, H; Sattler, W; Silbert, D; Sinner, F; Thueringer, A; Trauner, M; Zechner, R | 1 |
| Lankisch, TO; Weismüller, TJ | 1 |
| Dilger, K; Fromm, MF; Klatt, S; König, J | 1 |
| Denk, H; Durchschein, F; Fickert, P; Halilbasic, E; Krones, E; Moustafa, T; Pollheimer, MJ; Silbert, D; Thüringer, A; Trauner, M; Zollner, G | 1 |
| Abakumov, VZ; Belonovskaia, EB; Buko, VU; Lukivskaia, OIa; Naruta, EE | 1 |
| Halilbasic, E; Hofer, H; Kazemi-Shirazi, L; Kienbacher, C; Staufer, K; Trauner, M; Traussnigg, S | 1 |
| Claudel, T; Engelmann, R; Fickert, P; Fuchs, CD; Guenther, ND; Langner, C; Loebermann, M; Mueller, M; Mueller-Hilke, B; Österreicher, CH; Reisinger, EC; Sahin, E; Schramm, C; Schwinge, D; Sombetzki, M; Trauner, M | 1 |
| Claudel, T; Fickert, P; Fuchs, C; Halilbasic, E; Hofer, H; Kazemi-Shirazi, L; Kienbacher, C; Krones, E; Moustafa, T; Munda, P; Paumgartner, G; Pollheimer, M; Steinacher, D; Trauner, M; Traussnigg, S | 1 |
| Fuchs, C; Halilbasic, E; Hofer, H; Paumgartner, G; Trauner, M | 1 |
| Halilbasic, E; Kuntner, C; Langer, O; Mairinger, S; Müller, M; Römermann, K; Stieger, B; Trauner, M; Visentin, M; Wanek, T | 1 |
| Blomenkamp, K; Fickert, P; Marcus, N; Tang, Y; Teckman, J; Trauner, M | 1 |
| He, P; Lei, JH; Wang, CX; Yuan, WG; Zhang, CY | 1 |
| Eller, K; Fickert, P; Frauscher, B; Grahammer, F; Huber, TB; Kirsch, AH; Krones, E; Marschall, HU; Pollheimer, MJ; Racedo, S; Rosenkranz, AR; Ståhlman, M; Trauner, M; Wagner, K; Wahlström, A | 1 |
| Altorjay, I; Bergquist, A; Chapman, R; Denk, G; Färkkilä, M; Fickert, P; Greinwald, R; Halilbasic, E; Hirschfield, GM; Manns, MP; Marschall, HU; Nevens, F; Pröls, M; Reiter, FP; Schramm, C; Schrumpf, E; Spengler, U; Tornai, I; Trauner, M; Trivedi, P | 1 |
| Chazouillères, O | 1 |
| Fickert, P; Krones, E; Pollheimer, MJ; Rosenkranz, AR | 1 |
| Blomenkamp, KS; Fickert, P; Tang, Y; Teckman, JH; Trauner, M | 1 |
| Arab, JP; Arrese, M; Cabrera, D | 1 |
| Boettler, T; Demir, M; Fickert, P; Geier, A; Greinwald, R; Halilbasic, E; Hofmann, WP; Kluwe, J; Kremer, AE; Manns, MP; Petersen, J; Pröls, M; Rainer, F; Schattenberg, JM; Spreda, F; Teuber, G; Trauner, M; Traussnigg, S; Wiegand, J | 1 |
| Jiang, HX; Liang, ZY; Qin, SY; Su, SB; Wang, F; Yan, YD; Zhangdi, HJ | 1 |
| Majee, C; Mishra, R; Sahu, R | 1 |
| Alteneder, M; Baazim, H; Bergthaler, A; Boucheron, N; Claudel, T; Donner, C; Ellmeier, W; Fuchs, CD; Gülich, AF; Hainberger, D; Halilbasic, E; Hamminger, P; Khan, M; Lercher, A; Májek, P; Müller, AC; Ohradanova-Repic, A; Preglej, T; Remetic, J; Sakaguchi, S; Sandner, L; Scharnagl, H; Schatzlmaier, P; Stockinger, H; Stojakovic, T; Trauner, M; Viczenczova, C; Weichhart, T; Zhu, C | 1 |
| Dawson, PA; Feranchak, AP; Fuchs, CD; Gumber, S; Karpen, SJ; Li, J; Li, Q; Pachura, K; Rao, A; Trauner, M; Truong, JK | 1 |
10 review(s) available for 24-norursodeoxycholic acid and ursodeoxycholic acid
| Article | Year |
|---|---|
Cholestasis and cholestatic syndromes.
Topics: Animals; Bile Acids and Salts; Biological Transport; Cholangiopancreatography, Endoscopic Retrograde; Cholestasis; Humans; Prognosis; Syndrome; Ursodeoxycholic Acid | 2007 |
Medical and endoscopic therapy of primary sclerosing cholangitis.
Topics: Anti-Bacterial Agents; Catheterization; Cholagogues and Choleretics; Cholangitis, Sclerosing; Endoscopy, Digestive System; Humans; Immunosuppressive Agents; Stents; Ursodeoxycholic Acid | 2011 |
Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Topics: Bile Acids and Salts; Cholangitis, Sclerosing; Humans; Ligands; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2014 |
Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
Topics: Animals; Bile Duct Diseases; Humans; Liver Diseases; Metabolic Diseases; Signal Transduction; Ursodeoxycholic Acid | 2015 |
Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
Topics: Cholagogues and Choleretics; Cholangitis, Sclerosing; Gastrointestinal Microbiome; Humans; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2015 |
Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets.
Topics: Acetyl-CoA C-Acetyltransferase; Animals; CD4-Positive T-Lymphocytes; Disease Progression; Fatty Liver, Alcoholic; Hepatic Stellate Cells; Humans; Interleukins; Intracellular Signaling Peptides and Proteins; LIM Domain Proteins; Liver Cirrhosis; Macrophages; MicroRNAs; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease; Resveratrol; Schistosomiasis; Signal Transduction; Stilbenes; T-Lymphocytes, Regulatory; Triterpenes; Ursodeoxycholic Acid; Ursolic Acid; Virus Diseases | 2016 |
Cholemic nephropathy - Historical notes and novel perspectives.
Topics: Acute Kidney Injury; Animals; Bile Acids and Salts; Bile Ducts; Bilirubin; Cholagogues and Choleretics; Cholestasis; Disease Models, Animal; Epithelial Cells; Hepatocytes; Humans; Jaundice, Obstructive; Kidney Tubules; Liver; Renal Elimination; Ursodeoxycholic Acid | 2018 |
UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.
Topics: Bile Acids and Salts; Cholestasis; Humans; Liver; Liver Diseases; Taurochenodeoxycholic Acid; Ursodeoxycholic Acid | 2019 |
Crosstalk network among multiple inflammatory mediators in liver fibrosis.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Hepatic Stellate Cells; Hepatocytes; Humans; Imidazoles; Inflammation; Inflammation Mediators; Liver; Liver Cirrhosis; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrimidinones; Signal Transduction; Sulfoxides; Ursodeoxycholic Acid | 2019 |
An insight into primary biliary cholangitis and its recent advances in treatment: semi-synthetic analogs to combat ursodeoxycholic-acid resistance.
Topics: Animals; Bile Acids and Salts; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholic Acids; Humans; Liver Cirrhosis, Biliary; Nitrates; Ursodeoxycholic Acid | 2020 |
2 trial(s) available for 24-norursodeoxycholic acid and ursodeoxycholic acid
| Article | Year |
|---|---|
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Topics: Adult; Alkaline Phosphatase; Cholangitis, Sclerosing; Cholestasis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Ursodeoxycholic Acid | 2017 |
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Cholagogues and Choleretics; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Lipids; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Treatment Outcome; Ursodeoxycholic Acid | 2019 |
23 other study(ies) available for 24-norursodeoxycholic acid and ursodeoxycholic acid
| Article | Year |
|---|---|
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
Topics: Animals; Bile Acids and Salts; CHO Cells; Cricetinae; Cricetulus; Drug Design; Drug Evaluation, Preclinical; Hormones; Humans; Ligands; Models, Molecular; Molecular Conformation; Receptors, G-Protein-Coupled; Stereoisomerism; Structure-Activity Relationship | 2008 |
Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).
Topics: Bile Acids and Salts; Cell Line; Cell Survival; Chromatography, Reverse-Phase; Chromatography, Thin Layer; Esophagus; Humans; Hydrophobic and Hydrophilic Interactions; Structure-Activity Relationship | 2010 |
Ursodeoxycholic acid amides as novel glucocorticoid receptor modulators.
Topics: Amides; Binding Sites; Binding, Competitive; Cell Line, Tumor; Dexamethasone; Esophageal Neoplasms; Fluorescence Resonance Energy Transfer; Glucocorticoids; HEK293 Cells; Humans; Ligands; Models, Molecular; NF-kappa B; Protein Transport; Radioligand Assay; Receptors, Glucocorticoid; Response Elements; Structure-Activity Relationship; Transcriptional Activation; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid | 2011 |
Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1).
Topics: Drug Discovery; HEK293 Cells; Hep G2 Cells; Humans; Models, Molecular; Protein Conformation; Receptors, G-Protein-Coupled; Substrate Specificity; Ursodeoxycholic Acid | 2014 |
5 beta-hydroxylation by the liver. Identification of 3,5,7-trihydroxy nor-bile acids as new major biotransformation products of 3,7-dihydroxy nor-bile acids in rodents.
Topics: Animals; Bile Acids and Salts; Bile Ducts; Biotransformation; Carbon Radioisotopes; Chenodeoxycholic Acid; Cricetinae; Dogs; Gas Chromatography-Mass Spectrometry; Glucose; Humans; Hydroxylation; In Vitro Techniques; Liver; Magnetic Resonance Spectroscopy; Rabbits; Rats; Species Specificity; Sulfates; Sulfur Radioisotopes; Taurine; Ursodeoxycholic Acid | 1993 |
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Bile Acids and Salts; Cholangitis, Sclerosing; Disease Models, Animal; Mice; Mice, Knockout; Ursodeoxycholic Acid | 2006 |
Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis.
Topics: Animals; Bile Ducts; Cholangitis, Sclerosing; Epithelial Cells; Hepatocytes; Humans; Ursodeoxycholic Acid | 2009 |
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice.
Topics: Animals; Cholestasis, Intrahepatic; Male; Mice; Ursodeoxycholic Acid | 2009 |
Pharmacotherapy of cholestatic liver diseases.
Topics: Bile; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis, Intrahepatic; Chronic Disease; Humans; Liver; Ursodeoxycholic Acid | 2010 |
Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Proliferation; Diet, Fat-Restricted; Disease Progression; Down-Regulation; Drug Evaluation, Preclinical; Fatty Liver; Hepatocytes; Intracellular Signaling Peptides and Proteins; Lipids; Liver; Liver Cirrhosis; Mice; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Ursodeoxycholic Acid | 2011 |
Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice.
Topics: Animals; Anti-Bacterial Agents; Bile Ducts; Cholagogues and Choleretics; Cholangitis; Colitis; Cytokines; Dextran Sulfate; Disease Models, Animal; Epithelial Cells; HEK293 Cells; Humans; Immunity, Innate; Inflammation Mediators; Keratin-19; Leukocyte Common Antigens; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Mice, Inbred CFTR; Mice, Knockout; Neomycin; NF-kappa B; Phosphorylation; Polymyxin B; src-Family Kinases; Time Factors; Toll-Like Receptor 4; Transfection; Ursodeoxycholic Acid | 2011 |
Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Bile Acids and Salts; Cell Proliferation; Cholestasis, Intrahepatic; Chronic Disease; Dietary Fats; Disease Models, Animal; Disease Progression; Fatty Acids; Female; Fenofibrate; Gene Expression Profiling; Gene Expression Regulation; Hepatitis; Hypolipidemic Agents; Lipid Metabolism; Liver; Liver Cirrhosis; Metabolomics; Mice; Mice, Knockout; Oligonucleotide Array Sequence Analysis; PPAR gamma; Pregnancy; Prenatal Exposure Delayed Effects; Triglycerides; Ursodeoxycholic Acid | 2012 |
Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.
Topics: Cloning, Molecular; HEK293 Cells; Hepatocytes; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Dependent; Organic Anion Transporters, Sodium-Independent; Solute Carrier Organic Anion Transporter Family Member 1B3; Symporters; Ursodeoxycholic Acid | 2012 |
Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
Topics: Adenosine Triphosphate; Animals; Bicarbonates; Cholestasis; Humans; Male; Mice; Mice, Inbred C57BL; Ursodeoxycholic Acid | 2013 |
[Preventive administration of new UDCA derivatives in experimental alcoholic steatohepatitis].
Topics: Acetylcysteine; Alkaline Phosphatase; Animals; Cholagogues and Choleretics; Diet; Ethanol; Fatty Liver, Alcoholic; Female; gamma-Glutamyltransferase; Liver; Protective Agents; Rats; Rats, Wistar; Triglycerides; Tumor Necrosis Factor-alpha; Ursodeoxycholic Acid | 2013 |
24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
Topics: Animals; Cholagogues and Choleretics; Disease Models, Animal; Drug Monitoring; Granuloma; Immunohistochemistry; Inflammation; Liver Cirrhosis; Lymphocyte Activation; Mice; Schistosomiasis mansoni; T-Lymphocytes; Treatment Outcome; Ursodeoxycholic Acid | 2015 |
Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Biological Transport; CHO Cells; Cholestasis; Ciprofloxacin; Cricetulus; Disease Models, Animal; Female; Fluorine Radioisotopes; Liver; Mice, Knockout; Multidrug Resistance-Associated Proteins; Organ Specificity; Positron-Emission Tomography; Substrate Specificity; Tissue Distribution; Ursodeoxycholic Acid | 2016 |
Autophagy induced by exogenous bile acids is therapeutic in a model of α-1-AT deficiency liver disease.
Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Animals; Autophagy; Cells, Cultured; Deoxycholic Acid; Disease Models, Animal; Genetic Predisposition to Disease; Humans; Liver; Liver Cirrhosis; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Phenotype; Transfection; Ursodeoxycholic Acid | 2016 |
NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.
Topics: Animals; Bile Acids and Salts; Cholestasis; Disease Models, Animal; Fibrosis; Kidney; Kidney Diseases; Ligation; Lipocalin-2; Male; Mice; Mice, Inbred C57BL; Nephritis, Interstitial; Ursodeoxycholic Acid | 2017 |
24-Norursodeoxycholic acid in patients with primary sclerosing cholangitis: A new "urso saga" on the horizon?
Topics: Cholangitis, Sclerosing; Cholestasis; Humans; Ursodeoxycholic Acid | 2017 |
NorUDCA promotes degradation of α1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway.
Topics: Adenylate Kinase; alpha 1-Antitrypsin; Animals; Autophagy; Autophagy-Related Protein-1 Homolog; Disease Models, Animal; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Liver; Liver Diseases; Mice; Mutant Proteins; Proteolysis; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Ursodeoxycholic Acid | 2018 |
24-Norursodeoxycholic acid reshapes immunometabolism in CD8
Topics: Animals; CD8-Positive T-Lymphocytes; Disease Models, Animal; Inflammation; Liver; Mice; Mice, Inbred C57BL; Ursodeoxycholic Acid | 2021 |
Active enterohepatic cycling is not required for the choleretic actions of 24-norUrsodeoxycholic acid in mice.
Topics: Animals; Bicarbonates; Bile Acids and Salts; Cholagogues and Choleretics; Membrane Transport Proteins; Mice; Ursodeoxycholic Acid | 2023 |